NEW

Health Care Leaders Form Trustworthy & Responsible AI Network (TRAIN)

Monday, at the HIMSS 2024 Global Health Conference, a new consortium of healthcare leaders announced the creation of the Trustworthy & Responsible AI Network (TRAIN), which aims to operationalize responsible AI principles to improve the quality, safety and...

EPA Rule to Slash EtO Emissions, Reduce Cancer Risk

The U.S. Environmental Protection Agency has announced a rule that will reduce lifetime cancer risks for people living near commercial sterilization facilities across the country. The final amendments to the air toxics standards for ethylene oxide commercial...

AI Revolutionizes General Surgery, says GlobalData

Artificial intelligence (AI) integration in general surgery has surged, promising revolutionary advancements in precision and patient outcomes. AI tools have transformed preoperative planning, intraoperative assistance, and postoperative care, enhancing diagnostic...

Study Shows Potential for Using AI Tools to Detect Healthcare-Associated Infections

A new proof-of-concept study published today in the American Journal of Infection Control (AJIC) reports that artificial intelligence (AI) technologies can accurately identify cases of healthcare-associated infections (HAI) even in complex clinical scenarios. The...

Siemens’ PETNET Solutions to Provide Pet Radiopharmaceutical Services for the U.S. Oncology Network

Siemens’ PETNET Solutions has announced a three-year agreement with the U.S. Oncology Network to supply its entire portfolio of FDA-approved PET radiopharmaceutical agents at each of PETNET Solutions’ current Good Manufacturing Practices-certified locations throughout the United States. The U.S. Oncology Network is one of the nation’s largest networks of community-based oncology physicians, conducting roughly 60,000 positron emission tomography (PET) scans annually. This agreement also extends to community practices engaged in McKesson Specialty Health’s Onmark Select Program. Under the agreement, Siemens’ PETNET Solutions also will provide the U.S. Oncology Network-affiliated practices and Onmark Select Practices with its comprehensive portfolio of products and services to expand patient access to premium PET imaging services.

PET/CT imaging also plays a role in the evaluation and treatment monitoring of cancer patients. The high contrast and sharp delineation of molecular resolution made possible through PET imaging is vital for tumor identification and treatment, enabling physicians to determine whether cancer is present, whether it has metastasized, and whether treatment is effective. Because PET imaging measures molecular activity, it can accurately characterize a tumor’s malignant or benign state as well as confirm metastasis – enabling proper staging and facilitating suitable treatment protocols.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X